Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution
Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution |
|
https://doi.org/10.18632/oncotarget.291
Justin Stebbing,
Aleksandra Filipović,
and Georgios Giamas
|
| 428-429 |
Is nanomedicine still promising?
Is nanomedicine still promising? |
|
https://doi.org/10.18632/oncotarget.295
Pubudu M. Peiris,
and Efstathios Karathanasis
|
| 430-432 |
Heat shock proteins and cancer therapy: The trail grows hotter!
Heat shock proteins and cancer therapy: The trail grows hotter! |
|
https://doi.org/10.18632/oncotarget.294
John R. Subjeck,
and Elizabeth A. Repasky
|
| 433-434 |
Elevated PI3K signaling drives multiple Breast Cancer subtypes
Elevated PI3K signaling drives multiple Breast Cancer subtypes |
|
https://doi.org/10.18632/oncotarget.285
Jessica Adams,
Nathan F. Schachter,
Jeff C. Liu,
Eldad Zacksenhaus,
and Sean Eoin Egan
|
| 435-447 |
The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas
The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas |
|
https://doi.org/10.18632/oncotarget.283
Linus Plym Forshell,
Yongmei Li,
Tacha Zi Plym Forshell,
Martina Rudelius,
Lisa Nilsson,
Ulrich Keller,
and Jonas Nilsson
|
| 448-460 |
Strong Inhibition of Xenografted Tumor Growth by Low-Level Doses of [32P]ATP
Strong Inhibition of Xenografted Tumor Growth by Low-Level Doses of [32P]ATP |
|
https://doi.org/10.18632/oncotarget.289
Yulan Cheng,
Jian Yang,
Rachana Agarwal,
Gilbert M. Green,
Ron C. Mease,
Martin G. Pomper,
Stephen J. Meltzer,
and John M. Abraham
|
| 461-466 |
Phosphorylation of AKT: a Mutational Analysis.
Phosphorylation of AKT: a Mutational Analysis. |
|
https://doi.org/10.18632/oncotarget.293
Jonathan R. Hart,
and Peter K. Vogt
|
| 467-476 |
Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells
Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells |
|
https://doi.org/10.18632/oncotarget.274
Francesco Acquati,
Laura Monti,
Marta Lualdi,
Marco Fabbri,
Maria Grazia Sacco,
Laura Gribaldo,
and Roberto Taramelli
|
| 477-484 |
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies |
|
https://doi.org/10.18632/oncotarget.281
Francesco Passamonti,
Margherita Maffioli,
Domenica Caramazza,
and Mario Cazzola
|
| 485-490 |
p21-activated kinase 1: PAK’ed with potential
p21-activated kinase 1: PAK’ed with potential |
|
https://doi.org/10.18632/oncotarget.271
Christy Ong,
Adrian Jubb,
Wei Zhou,
Peter Haverty,
Adrian Harris,
Marcia Belvin,
Lori Friedman,
Hartmut Koeppen,
and Klaus Hoeflich
|
| 491-496 |
RIP Kinase-Mediated Necrosis as an Alternative Mechanism of Photoreceptor Death
RIP Kinase-Mediated Necrosis as an Alternative Mechanism of Photoreceptor Death |
|
https://doi.org/10.18632/oncotarget.286
Yusuke Murakami,
Joan W. Miller,
and Demetrios G. Vavvas
|
| 497-509 |
Targeting mTOR for the treatment of AML. New agents and new directions.
Targeting mTOR for the treatment of AML. New agents and new directions. |
|
https://doi.org/10.18632/oncotarget.290
Jessica K. Altman,
Antonella Sassano,
and Leonidas C. Platanias
|
| 510-517 |
A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation
A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation |
|
https://doi.org/10.18632/oncotarget.296
Erik A. Nelson,
Sreenath V. Sharma,
Jeffrey Settleman,
and David A. Frank
|
| 518-524 |
